source
- Tirabrutinib and CAR T-cell therapy show promise for relapsed/refractory primary CNS lymphomaExperts highlighted emerging data on tirabrutinib and CAR T-cell therapy as potential new options for patients with relapsed or refractory primary central nervous system lymphoma. CAR T-cell thera…
- Valneva to cut up to 15% of workforce as travel slowdown lowers vaccine demandValneva, a French vaccine developer, announced it will lay off between 10% and 15% of its employees. The cuts are linked to a decline in demand for travel vaccines, which the company says is drive…